FDA Brief

Warning letters Biologics

FDA warning letter to

Mark S. Denker, M.D., PA dba Palm Beach Fertility Center

High riskIssued Nov 17, 2022Posted Feb 7, 2023Division of Biological Products Operations I

FDA warns Boca Raton fertility center over failures to screen sperm and egg donors for infectious disease risk.

What happened

FDA inspected Palm Beach Fertility Center in Boca Raton, Florida, between May 31 and June 6, 2022, and found significant deviations from the rules for human cells, tissues, and cellular and tissue-based products (HCT/Ps), which cover donated reproductive tissue. Donors who reported risk factors for infectious disease were still cleared as eligible, the donor questionnaire left out required risk questions, and eligibility records were missing required details. FDA also said the firm's June 24, 2022 response was inadequate, and that many of the same problems were cited in a 2018 inspection and an unanswered 2018 Untitled Letter.

What FDA found

  1. Donors who said they had sex with another man in the past five years, or had lived in Europe for five years or more since 1980, were still ruled eligible, when the rules require ruling them ineligible.

    21 CFR 1271.75(d)(1)
  2. The donor medical history form did not ask about recent syphilis treatment, recent West Nile virus positive tests, blood transfusions in France since 1980, or living at certain US military bases in Europe.

    21 CFR 1271.75(a)(1)
  3. Records of donor eligibility decisions did not include the name of the person who made the decision or the date it was made.

    21 CFR 1271.55(d)(1)(iii)
  4. A donor whose specimen tested positive for CMV total antibody was recorded in the summary of records as negative, and semen was recovered from that donor.

    21 CFR 1271.55(b)(2)
  5. For several donors ruled ineligible, the summary of records did not give the reason, or gave a reason that did not match the donor's records.

    21 CFR 1271.55(b)(4)
  6. Written procedures did not require HIV, hepatitis B, hepatitis C and West Nile virus NAT testing, and stated that a positive hepatitis B surface antigen test may not make a donor ineligible.

    21 CFR 1271.47(a)

What FDA wants

FDA asks the firm to respond in writing within 15 working days describing the specific corrections and how it will prevent recurrence, with supporting documentation. Until then, oocytes, semen and embryos from donors whose screening or testing was incomplete must stay in quarantine.

Who should pay attention

  • fertility clinics and sperm or egg banks that share or receive donor tissue
  • clinics and labs that perform donor screening and eligibility determinations
  • patients receiving donor sperm, eggs or embryos

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk